tiprankstipranks
Inhibikase Therapeutics (IKT)
NASDAQ:IKT
US Market

Inhibikase Therapeutics (IKT) Income Statement

Compare
168 Followers

Inhibikase Therapeutics Income Statement

Last quarter (Q3 2024), Inhibikase Therapeutics's total revenue was $0.00, a decrease of -100.00% from the same quarter last year. In Q3, Inhibikase Therapeutics's net income was $-5.78M. See Inhibikase Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 260.50K$ 123.44K$ 3.10M$ 698.47K$ 1.12M
Gross Profit
$ -13.36M$ 116.72K$ -8.26M$ -195.33K$ -1.43M
Operating Expenses
$ 6.73M$ 18.13M$ 14.77M$ 2.82M$ 5.70M
Depreciation and Amortization
$ 177.40K$ 6.72K$ 14.77M$ 2.82M$ 5.70M
EBITDA
$ -19.91M$ -18.12M$ -14.77M$ -2.82M$ -5.70M
Operating Income
$ -20.09M$ -18.13M$ -14.77M$ -2.82M$ -5.70M
Other Income/Expenses
$ 1.06M$ 74.45K$ -19.92K$ -29.40K$ -24.84K
Pretax Income
$ -19.03M$ -18.05M$ -14.79M$ -2.85M$ -5.72M
Net Income
$ -19.03M$ -17.91M$ -14.81M$ -2.88M$ -5.75M
Per Share Metrics
$ ―$ ―$ ―$ ―$ ―
Basic EPS
$ -3.57$ -4.26$ -4.88$ -1.72$ -3.34
Diluted EPS
$ -3.57$ -4.26$ -4.88$ -1.72$ -3.34
Weighted Average Shares Outstanding
5.33M 4.20M 3.03M 1.68M 1.72M
Weighted Average Shares Outstanding (Diluted)
5.33M 4.20M 3.03M 1.68M 1.72M
Currency in USD

Inhibikase Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis